Thyroxine for acute kidney injury

  • Protocol
  • Intervention



This is the protocol for a review and there is no abstract. The objectives are as follows:

To evaluate at the benefits and harms of thyroxine for the treatment of AKI by any cause in hospitalised adult patients. The following will be addressed:

  • To determine whether the use of thyroxine versus placebo with or without supplemental treatment (such as furosemide, dopamine or ANP) for AKI is associated with a reduction in all-cause mortality rates.

  • To determine whether the use of thyroxine is associated with shorter duration of AKI, decreased need for dialysis for AKI, reduction in the rate of progression to end-stage kidney disease (ESKD).

  • To determine any harmful effects associated with the use of thyroxine (e.g. hypotension, arrhythmias).